Purpose The genetic polymorphism was one of the major considerations for adjusting doses
of warfarin in Thai individuals. As a result, new oral anticoagulants (NOACs) were …

Background This study aimed to assess the cost-effectiveness of non-vitamin K antagonist
oral anticoagulants (NOACs) in comparison with warfarin using data from real practice …

Abstract Introduction Novel oral anticoagulants (NOACs) and warfarin care bundles (eg
genotyping, patient self-testing or self-management) are alternatives to usual warfarin care …

Background Atrial fibrillation (AF) is a severe epidemiological and public health concern
among the elderly population worldwide, with substantial economic and social burdens …

Background Non-vitamin K antagonist oral anticoagulants (NOACs) have been
recommended as preferred options for stroke prevention in patients with atrial fibrillation …

Background Non-vitamin K oral antagonist anticoagulants (NOACs) have been widely used
in stroke prevention in atrial fibrillation (SPAF). The aim of this study was to compare the …

ABSTRACT BACKGROUND The decision as to whether to use more expensive novel oral
anticoagulants (NOACs) or invest resources for quality improvement of warfarin therapy …

Introduction: Non-valvular atrial fibrillation (NVAF) and ischemic stroke are collectively
associated with annual hospital costs of tens of billions of dollars in the USA. Oral …

Objective: Results of randomized clinical trials (RCT) demonstrate that novel oral
anticoagulants (NOAC) are effective therapies for reducing the risk of stroke in non-valvular …

What is known and objective With the high cost, the long‐term persistence of new oral
anticoagulants (NOACs) was lower than that of warfarin in Chinese patients with non …